Neuroprotective and Cytotoxic Profiling of Novel Hydrazone Derivatives in a SH-SY5Y Neurodegeneration Model
DOI:
https://doi.org/10.5281/zenodo.22664640Keywords:
hydrazone derivatives, SH-SY5Y neuroblastoma, 6-hydroxydopamine neurotoxicity, oxidative stress neuroprotection, Parkinson's diseaseAbstract
Background: Oxidative stress and mitochondrial dysfunction drive dopaminergic neuronal loss in Parkinson's disease, and
hydrazone derivatives have repeatedly shown combined radical-scavenging and neuroprotective activity in SH-SY5Y
neuroblastoma models of this pathology.
Objective: We synthesized a structurally graded series of seven aroylhydrazones sharing an indole-3-ylacetohydrazide core,
differing only in the aromatic aldehyde condensed onto it, and evaluated their cytotoxicity and neuroprotective potential against
6-hydroxydopamine (6-OHDA)-induced injury in SH-SY5Y cells.
Methods: Retinoic acid-differentiated SH-SY5Y cells were challenged with 6-OHDA (100 uM, 24 h) with or without prior exposure to
compounds MO-1 to MO-7 (1-50 uM). Viability (MTT), intracellular reactive oxygen species (DCFH-DA), mitochondrial membrane
potential (JC-1), and caspase-3 activity were measured against ascorbic acid and selegiline reference controls.
Results: 6-OHDA reduced viability to 47% of control and increased ROS, mitochondrial depolarization, and caspase-3 activation.
Neuroprotection tracked aryl substitution: the catechol derivative MO-3 was the most active compound across all four endpoints
(EC50 6.8 uM for viability recovery, 84% viability, 36% residual ROS, 81% preserved mitochondrial potential, 1.6-fold caspase-3
activation), followed by the vanillin-type MO-4 and hindered-phenol MO-7. The unsubstituted (MO-1) and nitro-substituted (MO-6)
hydrazones were essentially inactive. Caspase-3 protection correlated more closely with mitochondrial membrane potential
preservation (r = 0.85) than with ROS suppression alone (r = 0.71).
Conclusion: Catechol-type substitution confers the strongest neuroprotective profile within this hydrazone series, acting
predominantly through mitochondrial preservation rather than cytosolic radical scavenging alone, and MO-3 represents a
reasonable lead for further mechanistic and in vivo evaluation as a hydrazone-based neuroprotectant against Parkinsonian
oxidative neurodegeneration.
References
Chang KH, Chen CM (2020) The Role of Oxidative Stress in Parkinson's Disease. Antioxidants, 9(7):597, DOI:10.3390/antiox9070597.
Puspita L, Chung SY, Shim JW (2017) Oxidative stress and cellular pathologies in Parkinson's disease. Molecular Brain, 10:53, DOI:10.1186/s13041-017-0340-9.
Xicoy H, Wieringa B, Martens GJM (2017) The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Molecular Neurodegeneration, 12:10, DOI:10.1186/s13024-017-0149-0.
Ioghen OC, Ceafalan LC, Popescu BO (2023) SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research-Old Practice for New Trends. Journal of Integrative Neuroscience, 22(1):20, DOI:10.31083/j.jin2201020.
Korecka JA, van Kesteren RE, Blaas E, Spitzer SO, Kamstra JH, Smit AB, Swaab DF, Verhaagen J, Bossers K (2013) Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS ONE, 8(5):e63862, DOI:10.1371/journal.pone.0063862.
Ferlazzo N, Cirmi S, Maugeri A, Russo C, Lombardo GE, Gangemi S, Calapai G, Mollace V, Navarra M (2020) Neuroprotective Effect of Bergamot Juice in 6-OHDA-Induced SH-SY5Y Cell Death, an In Vitro Model of Parkinson's Disease. Pharmaceutics, 12(4):326, DOI:10.3390/pharmaceutics12040326.
Betharia S, Rondon-Ortiz AN, Brown DA (2019) Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells. Neurochemical Research, 44(8):1878-1892, DOI:10.1007/s11064-019-02823-3.
Hyon JY, Lee HJ, Yun SH, Han EH, Chung YH (2023) Comparative proteomics study of mitochondrial electron transport system modulation in SH-SY5Y cells following MPP+ versus 6-OHDA-induced neurodegeneration. Journal of Analytical Science and Technology, 14:1, DOI:10.1186/s40543-022-00365-y.
Kondeva-Burdina M, Mateev E, Angelov B, Tzankova V, Georgieva M (2022) In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitory Effects of Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson's Disease. Molecules, 27(23):8485, DOI:10.3390/molecules27238485.
Anastassova N, Aluani D, Hristova-Avakumova N, Tzankova V, Kondeva-Burdina M, Rangelov M, Todorova N, Yancheva D (2022) Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease. Antioxidants, 11(5):884, DOI:10.3390/antiox11050884.
Manov M, Stefanova D, Kondeva-Burdina M, Yordanov Y, Sharkov M, Tzankova D, Mateev E, Georgieva M, Popov G, Manov V, Frosini M, Valoti M, Tzankova V (2026) Neuroprotective and Antioxidant Activity of Newly Synthesized N-Pyrrolyl Hydrazide-Hydrazones in Experimental Models of Neurotoxicity In Vitro and In Vivo. International Journal of Molecular Sciences, 27(1):370, DOI:10.3390/ijms27010370.
Karatchobanov V, Mateev E, Valkova I, Kondeva-Burdina M, Georgieva M (2025) Novel Pyrrole-Based Hydrazide-Hydrazones: Synthesis, In Vitro Evaluation of Antioxidant and Neuroprotective Activity, In Silico ADME, and DFT Studies. Antioxidants, 15(6):666, DOI:10.3390/antiox15060666.
Georgieva M, Sharkov M, Mateev E, Tzankova D, Popov G, Manov V, Zlatkov A, Simeonova R, Kondeva-Burdina M (2025) Classical Paal-Knorr Cyclization for Synthesis of Pyrrole-Based Aryl Hydrazones and In Vitro/In Vivo Evaluation on Pharmacological Models of Parkinson's Disease. Molecules, 30(15):3154, DOI:10.3390/molecules30153154.
Kumar S, Oh JM, Prabhakaran P, Awasti A, Kim H, Mathew B (2024) Isatin-tethered halogen-containing acylhydrazone derivatives as monoamine oxidase inhibitor with neuroprotective effect. Scientific Reports, 14(1):1264, DOI:10.1038/s41598-024-51728-x.
Karabelyov V, Angelova VT, Sharkov M, Todorova N, Kondeva-Burdina M (2023) In vitro/in vivo effects of some new 2,5-disubstituted 1,3,4-oxadiazole and hydrazone analogues targeting Parkinson's disease. Journal of Molecular Structure, 1288:135755, DOI:10.1016/j.molstruc.2023.135755.
de Freitas Silva M, Cristancho Ortiz CJ, Coelho LF, et al. (2024) Synthesis and pharmacological evaluation of novel N-aryl-cinnamoyl-hydrazone hybrids designed as neuroprotective agents for the treatment of Parkinson's disease. Bioorganic Chemistry, 150:107587, DOI:10.1016/j.bioorg.2024.107587.
Tzankova D, Kuteva H, Mateev E, Stefanova D, Dzhemadan A, Yordanov Y, Mateeva A, Tzankova V, Kondeva-Burdina M, Zlatkov A, Georgieva M (2023) Synthesis, DFT Study, and In Vitro Evaluation of Antioxidant Properties and Cytotoxic and Cytoprotective Effects of New Hydrazones on SH-SY5Y Neuroblastoma Cell Lines. Pharmaceuticals, 16(9):1198, DOI:10.3390/ph16091198.
Omidi S, Kakanejadifard A (2020) A review on biological activities of Schiff base, hydrazone, and oxime derivatives of curcumin. RSC Advances, 10(50):30186-30202, DOI:10.1039/D0RA05720G.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2):55-63, DOI:10.1016/0022-1759(83)90303-4.
Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A (2012) JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death & Disease, 3:e430, DOI:10.1038/cddis.2012.171.
Uehara T, Kikuchi Y, Nomura Y (1999) Caspase activation accompanying cytochrome c release from mitochondria is possibly involved in nitric oxide-induced neuronal apoptosis in SH-SY5Y cells. Journal of Neurochemistry, 72(1):196-205, DOI:10.1046/j.1471-4159.1999.0720196.x.
